Search Results for agency_names:"Justice Department"

The Drug Enforcement Administration (DEA) issued an order to revoke Dr. David Israel's registration to handle controlled substances after he was found to lack the authority to practice medicine in New York. This decision was based on his failure to request a hearing and allegations that he issued prescriptions outside the usual course of professional practice and for non-legitimate medical purposes. Dr. Israel also allegedly allowed another individual to use his credentials to issue prescriptions unlawfully. His registration revocation is seen as consistent with ensuring public safety and compliance with the Controlled Substances Act.

Patheon API Inc. has applied to the Drug Enforcement Administration to register as a bulk manufacturer of several controlled substances. The registration would allow the company to import these substances as reference standards for research and development in its API Manufacturing operations. Interested parties, including current registered bulk manufacturers, can submit comments or objections electronically by April 21, 2025, and may also request a hearing on the application by the same date. Comments submitted will be tracked, and successful submissions will receive a Comment Tracking Number.

The Consortium for Execution of Rendezvous and Servicing Operations (CONFERS) has updated its membership and filed these changes with the Attorney General and the Federal Trade Commission. New members include ClearSpace SA from Switzerland and several U.S.-based companies, while Effective Space from the United Kingdom has left the group. The purpose of the filing is to extend the law that limits how much money can be recovered in antitrust lawsuits against CONFERS. The group plans to continue notifying about membership changes in the future.

The Drug Enforcement Administration (DEA) issued an Order to Show Cause to Laura M. Bellew, a nurse practitioner from New Mexico, proposing to revoke her DEA registration because she no longer has the authority to handle controlled substances in New Mexico. This is because her nursing licenses were suspended by the New Mexico State Board of Nursing in January 2023. Bellew did not request a hearing to contest the charges, effectively admitting the DEA's allegations. As a result, the DEA decided to revoke her registration and deny any pending applications related to controlled substances in New Mexico.

The Department of Justice has proposed a consent decree related to a lawsuit against XTO Energy, Inc. for a 2018 gas well blowout in Ohio that released thousands of tons of methane. Under the proposed agreement, XTO would pay $8 million in penalties, conduct an audit of its operations, and undertake projects to reduce methane emissions. The public is invited to comment on this proposal within 30 days of its announcement. The decree can be reviewed online, and comments may be submitted by email or mail.

The Drug Enforcement Administration (DEA) has announced that Livwell Michigan, LLC has applied to be registered as a bulk manufacturer of controlled substances, specifically marihuana, listed under Schedule I. The DEA will evaluate this application based on specific regulations and guidelines to ensure it complies with laws and has measures in place to prevent misuse. The public and other manufacturers have until April 26, 2021, to submit comments or objections regarding this application. If approved, Livwell Michigan, LLC would be allowed to produce marihuana for use in scientific and medical research, but not for other purposes.

The Defense Electronics Consortium (DEC) has filed notifications with the Attorney General and the Federal Trade Commission regarding changes in its membership under the National Cooperative Research and Production Act of 1993. This filing aims to ensure that antitrust plaintiffs can only recover actual damages under certain conditions. DEC has stated that it is no longer accepting new members but will continue updating membership changes. Previous notifications have been noted in the Federal Register on different dates, highlighting the organization's compliance with regulatory requirements.

ODVA, Inc. has filed notifications with the Attorney General and the Federal Trade Commission about changes in its membership under the National Cooperative Research and Production Act. This filing limits the recovery of antitrust plaintiffs to actual damages in certain situations. New members added to the group include companies from Japan, Malta, the United States, Germany, the United Kingdom, and Sweden, while companies from South Korea and the United States have withdrawn. The membership remains open, and future notifications will be made for any changes.

Pharmaron Manufacturing Services (US), LLC has applied to the Drug Enforcement Administration (DEA) to become a bulk manufacturer of certain controlled substances. This registration is intended to allow the company to produce materials for clinical trials. Interested parties can submit comments or request a hearing on the application by May 27, 2025, via the Federal eRulemaking Portal. The application was officially filed on February 11, 2025, and no other activities related to these substances are authorized beyond clinical trial production.

The Justice Department's Criminal Justice Information Services (CJIS) Division is seeking public comments on a proposed information collection activity. This involves the FBI Records Modification Form (FD-1115), which helps ensure criminal history information is accurately managed in compliance with privacy regulations. The form is necessary for state, local, Tribal, and Federal governments to edit their records accurately since manual updates may be required. Comments will be accepted until March 17, 2025, and focus on the necessity, accuracy, enhancement, and minimization of respondent burden related to the information collection.